

CLAIMS

WHAT IS CLAIMED IS:

- Sub A1
- 5 1. Use of tissue factor or a fragment thereof for influencing blood vessel formation.
2. Use according to claim 1, wherein the influence is an activation of blood vessel formation.
- 10 3. Use according to claim 2, wherein the blood vessel formation for wound healing is concerned.
- 15 4. Use according to claim 2 or 3, wherein the wound healing in the case of diabetes mellitus, vasculitis, arterial conclusive disease, chronic venous and infected ulcer, innervation impairment, decubital gangrene and weak sutures in the case of operations is concerned.
- 20 5. Use according to claim 2 or 3, wherein the blood vessel formation in the case of arteriosclerosis, Crohn's disease and ulcerative colitis, diabetic retinopathy and deep venous thrombosis of the legs/ulcus cruris is concerned.
- 25 6. Use according to claim 2, wherein the blood vessel formation for replacing impaired blood vessels is concerned.
7. Use according to any one of claims 1 to 6, wherein the tissue factor or a fragment thereof is present as expressible nucleic acid.
- 30 8. Use according to claim 7, wherein the expression of the nucleic acid is transient.
9. Use according to claim 7 or 8, wherein the nucleic acid is a DNA.

Sub A1

10. Use according to any one of claims 7 to 9, wherein the nucleic acid is controlled by a constitutive or inducible promoter.

5 11. Use according to any one of claims 7 to 10, wherein the nucleic acid is present in a Sindbis virus replicon vector.

12. Use according to any one of claims 7 to 10, wherein the nucleic acid is controlled by a CMV or SV40 promoter.

10 13. Use according to any one of claims 1 to 12, wherein the tissue factor is present in a liposome or on a carrier, particularly gold particle.

14. Use according to any one of claims 1 to 13, wherein the tissue factor is present in combination with further factors promoting the formation of blood vessels.

15 15. Use according to claim 14, wherein the factors are present as expressible nucleic acids.

16. Use according to claim 14 or 15, wherein one of the factors is VEGF.

20 17. Use according to any one of claims 1 to 16, wherein the tissue factor is present in a pharmaceutical composition.

25 18. Use according to claim 1, wherein the influence is an inhibition of blood vessel formation.

19. Use according to claim 18, wherein the tissue factor is present in the form of an antibody inhibiting it.

30 20. Use according to claim 18, wherein the tissue factor is present in the form of a nucleic acid, which has an antisense effect on the expression of tissue factor.

005280" 27 2260

Sub A2

sub 2

21. Use according to any one of claims 18 to 20, wherein the tissue formation is inhibited in a tumoral disease.

Adel B 7

5

10

15

20

25

30

09423712-082500

CLAIMS AS AMENDED UNDER ARTICLE 34

1. Use of tissue factor or a fragment thereof for the well-calculated therapeutic influence of blood vessel formation by induction of a local expression of a tissue factor
5 nucleic acid or by local application of a functional tissue factor protein.

2. Use according to claim 1, wherein the influence is an activation of blood vessel formation.

10 3. Use of a tissue factor or a fragment thereof for influencing the wound healing by induction of a local expression of a tissue factor nucleic acid or by local application of a functional tissue factor protein.

15 4. Use according to claim 3, wherein the wound healing in the case of diabetes mellitus, vasculitis, arterial conclusive disease, chronic venous and infected ulcer, innervation impairment, decubital gangrene and weak sutures in the case of operations is concerned.

20 5. Use according to claim 1 or 2, wherein the blood vessel formation in the case of arteriosclerosis, Crohn's disease and ulcerative colitis, diabetic retinopathy and deep venous thrombosis of the legs/ulcus cruris is concerned.

25 6. Use according to claim 1 or 2, wherein the blood vessel formation for replacing impaired blood vessels is concerned.

7. Use according to any one of claims 1 to 6, wherein the tissue factor or a fragment thereof is present as expressible nucleic acid.

30 8. Use according to claim 7, wherein the expression of the nucleic acid is transient.

9. Use according to claim 7 or 8, wherein the nucleic acid is a DNA.

10. Use according to any one of claims 7 to 9, wherein the nucleic acid is controlled by a constitutive or inducible promoter.

5

11. Use according to any one of claims 7 to 10, wherein the nucleic acid is present in a Sindbis virus replicon vector.

12. Use according to any one of claims 7 to 10, wherein the nucleic acid is controlled by a CMV or SV40 promoter.

10

13. Use according to any one of claims 1 to 12, wherein the tissue factor is present in a liposome or on a carrier, particularly gold particle.

15

14. Use according to any one of claims 1 to 13, wherein the tissue factor is present in combination with further factors promoting the formation of blood vessels.

15. Use according to claim 14, wherein the factors are present as expressible nucleic acids or functional proteins.

20

16. Use according to claim 14 or 15, wherein one of the factors is VEGF.

17. Use according to any one of claims 1 to 16, wherein the tissue factor is present in a pharmaceutical composition.

25

add
04

30